These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29781548)

  • 1. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
    Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
    Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput approaches for precision medicine in high-grade serous ovarian cancer.
    Govindarajan M; Wohlmuth C; Waas M; Bernardini MQ; Kislinger T
    J Hematol Oncol; 2020 Oct; 13(1):134. PubMed ID: 33036656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
    Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
    Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
    Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
    Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
    Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
    Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
    [No Abstract]   [Full Text] [Related]  

  • 17. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
    Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
    Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.